Lantern Pharma Receives FDA Clearance to Advance Breast Cancer Therapy into Clinical Trials
Lantern Pharma Inc. (Nasdaq: LTRN), an AI-driven biotech company focused on precision cancer therapies, has received FDA clearance for its Investigational New Drug (IND) application to begin a Phase 1b/2 clinical trial of LP-184 for Triple Negative Breast Cancer (TNBC). This milestone follows recent regulatory progress, including Orphan Drug Designation in 2023 and Fast Track Designation earlier this year. LP-184 is being developed using Lantern’s proprietary AI platform, RADR®, which accelerates the discovery and development of targeted cancer treatments.
Lantern Pharma Receives FDA Clearance to Advance Breast Cancer Therapy into Clinical Trials